Restoring p53 Function in Sarcomas Using MDM2 Inhibitors

Arwen Shah

Abstract

MDM2 is an E3 ubiquitin ligase and the principal negative regulator of the tumor suppressor gene TP53, maintaining cellular homeostasis through a tightly controlled feedback loop in which p53 transcriptionally activates MDM2, and MDM2, in turn, ubiquitinates p53 for degradation. In several sarcomas—particularly well-differentiated and dedifferentiated liposarcomas—MDM2 amplification at chromosome 12q15 suppresses p53 activity despite retention of a wild-type TP53 gene. This makes the p53-binding pocket of MDM2 an attractive therapeutic target in these tumors.

Over the past two decades, nine small-molecule MDM2 inhibitors have entered clinical trials, including RG7112, idasanutlin, SAR405838, HDM201, APG-115, navtemadlin, AMG-232, milademetan, and BI-907828, with seven advancing to later-stage evaluation. Although none have yet received regulatory approval, early-phase studies have demonstrated pharmacodynamic proof-of-concept, evidenced by p53 stabilization, induction of downstream targets such as p21, and tumor growth arrest in MDM2-amplified models and patients.

This study compares the effectiveness of these inhibitors in the context of MDM2-amplified sarcomas, where excessive MDM2 expression suppresses wild-type TP53 activity. Pharmacologic blockade of the p53–MDM2 interaction can release p53 from inhibition, thereby restoring its tumour-suppressive functions and inducing cell-cycle arrest or apoptosis in cancer cells.

Introduction

The tumor suppressor protein p53, encoded by the *TP53* gene, plays a crucial role in protecting the genome from damage. Often referred to as the ‘guardian of the genome,’ p53 halts the cell cycle and induces apoptosis (programmed cell death) or senescence (irreversible growth arrest) in response to DNA damage or cellular stress. In this way, p53 prevents the proliferation of potentially cancerous cells and helps maintain genomic stability (Wu & Maki, 2000).

Under normal conditions, the activity of p53 is tightly regulated by MDM2 (Mouse Double Minute 2)—a proto-oncogene that encodes an E3 ubiquitin ligase. MDM2 binds to the amino-terminal domain of p53 and tags it with ubiquitin, marking it for degradation by the proteasome. This process ensures that p53 levels remain low in non-stressed cells. Importantly, p53 itself activates the transcription of the *MDM2* gene, creating an autoregulatory negative feedback loop that maintains homeostasis (Cancer Cell Int., 2021).

In several cancers, particularly well-differentiated and dedifferentiated liposarcomas (WDLPS/DDLPS), *MDM2* is amplified at the 12q15 chromosomal locus, leading to excessive

degradation of p53. Notably, many of these tumors retain wild-type (non-mutated) p53, which makes them particularly sensitive to MDM2 inhibition strategies (Ray-Coquard et al., 2012).

The therapeutic rationale for MDM2 inhibition is to disrupt the MDM2–p53 interaction and thereby restore p53's tumor-suppressive functions. This can reactivate p53 signaling in cancers with wild-type p53, resulting in cell cycle arrest or apoptosis (Tisato et al., 2017).

This review explores the therapeutic implications of MDM2 inhibition in sarcomas, focusing on the evolution from Nutlin-3 to advanced clinical compounds like RG7112, Idasanutlin, and Milademetan. Special attention is given to the underlying mechanisms of action, resistance, and combination strategies to improve treatment outcomes in liposarcoma patients.

Tumor suppressor gene (TP53)

Tumor suppressor gene TP53 codes for protein p53 that regulates a plethora of genes to maintain homeostasis in the body. The transcription factor p53 (encoded by the TP53 gene) is often called the “guardian of the genome” because it plays a key role in maintaining genomic stability.
Under normal (unstressed) conditions, p53 protein levels remain low due to continuous breakdown by the cell’s protein recycling machinery.

When cells experience stress — such as DNA damage, low oxygen (hypoxia), or abnormal oncogene activation — p53 becomes stabilised and switched on. Once active, p53 turns on a set of target genes (Figure 1) that:

- Pause the cell cycle to allow DNA repair
- Trigger apoptosis (programmed cell death)
- Induce senescence (permanent cell-cycle arrest) if the damage is beyond repair

Two important examples of p53 target genes are CDKN1A (which produces the p21 protein to halt the G1 cell-cycle phase) and PUMA or BAX (which help trigger apoptosis).
This protective process is so important that loss of p53 function happens in roughly half of all human cancers (Marei et al., 2021). In tumors that have a normal (wild-type) TP53 gene, p53 can still be inactivated indirectly by changes in its regulators (Oliner et al., 2016).



Figure 1. Interaction network of TP53 showing key transcriptional targets and regulatory partners involved in cell cycle control, apoptosis, and stress response (Human Protein Atlas). The above diagram was accessed from the Structure & Interaction resource of 'The Human Protein Atlas'. The Human Protein Atlas is a Global Core Biodata Resource in life sciences, based at SciLifeLab.

MDM2 acts as a negative regulator of the TP53 gene

A primary negative regulator of p53 is MDM2 (Mouse Double Minute 2), an E3 ubiquitin ligase and proto-oncogene. MDM2 binds to the N-terminal transactivation domain of p53, blocking its transcriptional activity and adding ubiquitin tags that mark p53 for proteasomal degradation. This continuous surveillance maintains low basal p53 levels in unstressed cells. MDM2 itself is a transcriptional target of p53, creating an autoregulatory negative feedback loop as indicated in Figure 2: p53 activation induces MDM2 expression, and MDM2 then degrades p53 to restore homeostasis. This feedback ensures p53 is restrained under normal growth, but can rise rapidly under stress (Yao et al., 2024).



Figure 2. Regulation of p53 by MDM2 under homeostasis and stressed conditions.

Role of MDM2 in sarcomas

MDM2 is a protein that plays a significant role in several types of sarcomas, which are malignant tumors that originate from mesenchymal tissues such as bone, fat, muscle, and cartilage (Sbaraglia et al., 2020). These tumors include well-differentiated and dedifferentiated liposarcoma—a subtype arising from adipocytic (fat) tissue that frequently shows high-level amplification (Gambella et al., 2023). MDM2 amplification is a defining hallmark of such sarcomas, and its interaction with the tumor suppressor p53 has emerged as an actionable therapeutic target (Vassilev et al., 2004).

In certain sarcomas, particularly well-differentiated and dedifferentiated liposarcomas (WDLPS/DDLPS), the regulatory axis between MDM2 and p53 is hijacked by MDM2 gene amplification at chromosome 12q13–15 (Gambella et al., 2023). These tumors usually retain wild-type TP53, meaning that p53's inherent tumor-suppressive function is not lost to mutation. Instead, p53 is rendered inactive upstream by MDM2 overactivity. Pharmacological inhibition of MDM2 in this context can restore p53 function, triggering cell cycle arrest or apoptosis and providing a compelling therapeutic vulnerability unique to these genetic settings.



Figure 3. Location of the human MDM2 gene on chromosome 12 and corresponding nucleotide coordinates.

Source: NCBI Gene [Gene ID: 4193], National Center for Biotechnology Information. Available at: https://www.ncbi.nlm.nih.gov/gene/4193/

Cancer therapy with MDM2 Inhibitors

The development of MDM2 inhibitors is based on the observation that many sarcomas retain wild-type p53 but exhibit MDM2 gene amplification. This amplification results in excess MDM2 protein, which binds and degrades p53, suppressing its tumor-suppressive (TS) activity despite p53 itself being intact. By inhibiting the MDM2–p53 interaction, these drugs restore p53 function, reactivating its ability to induce cell-cycle arrest, senescence, and apoptosis in tumor cells. Following the proof-of-concept with Nutlin-3, successive generations of small-molecule inhibitors — notably RG7112, idasanutlin, and milademetan — have been developed and evaluated in preclinical and clinical settings. These key compounds and their effects in vivo and in vitro are reviewed in Table 1 below.

Table 1: The list of MDM2 inhibitors and their effects

Compound	Unique Feature or Strategy	Key Preclinical Findings	Clinical Findings / Status	Reference
Nutlin-3	First-in-class; revealed proteotoxic stress and combination opportunities	Strong p53 activation; synergizes with chemotherapy and ferroptosis inducers	Proof-of-concept only; not clinically developed	Vassilev et al., 2004

RG7112	First clinical-stage oral Nutlin-based inhibitor	Stabilizes p53; tumor growth inhibition in MDM2-amplified models	Limited to disease stabilization; high hematologic toxicity	Ray-Coquard et al., 2012
Idasanutlin (RG7388)	Improved potency; synergy with kinase and proteasome inhibitors	Potent p53 reactivation and tumor regression	AML Phase III failure; limited sarcoma data	Khurana et al., 2019
Milademetan (RAIN-32)	Intermittent dosing (3/14) reduces hematologic toxicity	Potent p53 induction; tumor growth suppression	Phase III in liposarcoma showed comparable efficacy to chemotherapy with better safety	Gounder et al., 2023
ALRN-6924	Stapled peptide; dual MDM2/MDMX inhibition; less myelosuppression	Effective dual inhibition; overcomes MDMX-driven resistance	Disease control with minimal hematologic toxicity	Saleh et al., 2021
Navtemadlin (KRT-232)	Highly potent; radiosensitising properties	Enhances radiation-induced tumor cell death	Ongoing sarcoma+radiation combo trials; Phase III in myelofibrosis	Hanna et al. 2019
MI-77301 (SAR405838)	Spirooxindole scaffold; apoptosis inducer	Induces apoptosis in DDLPS models	Early clinical activity was limited; further development slowed	Bill et al., 2016
BI-907828	Long-acting oral spirooxindole analog; sustained p53 activation	Complete regressions in DDLPS patient-derived xenografts	Promising early clinical results in sarcoma	Boehringer Ingelheim, 2025

Siremadlin (HDM201)	Selective 2nd-gen; synergizes with DNA-damaging chemotherapy	Tumor regression with combination approaches	Encouraging early-phase data with intermittent dosing	Novartis Pharmaceuticals, 2021
APG-115	Immunomodulatory effects; enhances PD-1 blockade synergy	Activates antitumor immunity	Early signs of durable disease control in solid tumors	Fang et al., 2019
AMG-232	Highest binding affinity; rapid p53 activation	Potent tumor inhibition in xenografts	Partial responses in MDM2-amplified tumors; ongoing combo studies	Gluck WL et al., 2019

Nutlin-3 (p53-MDM2 inhibitor)

Nutlin-3 is a landmark small-molecule inhibitor from the cis-imidazoline chemical series, discovered by Vassilev and colleagues at Roche (Arya et al., 2010). By occupying the p53-binding site on MDM2, it releases and stabilises p53, rapidly reactivating its tumor suppressor functions.

(a)



(b)

Figure 4.
(a) Crystal structure of MDM2 bound to Nutlin-3a (PDB ID: 4HG7). The MDM2 protein is shown in ribbon format (magenta), and the Nutlin molecule is shown interacting at 11 residues, highlighted in yellow.
(b) Protein sequence annotation of MDM2 (UniProt: Q00987), displaying the structural features and positions of Nutlin-interacting residues.

Source: These figures was generated using iCn3D ("I see in 3D"), a WebGL-based viewer developed by NCBI for interactive visualization of three-dimensional macromolecular structures and their chemical interactions.

In sarcoma models with wild-type TP53 and MDM2 overexpression—including Ewing sarcoma and osteosarcoma cell lines—Nutlin-3 strongly stimulated p53-dependent gene expression (notably p21 and PUMA), resulting in cell-cycle arrest and apoptosis. Significantly, Nutlin-3 induced robust tumor regressions in sarcoma xenograft models (Sonnemann et al., 2011). Beyond reactivating canonical p53 programs, Nutlin-3 also exposes new cellular vulnerabilities that can be exploited therapeutically:

Proteotoxic stress: Ludwig et al. (2023) showed that Nutlin-3 treatment increases the production and breakdown of proteins inside liposarcoma cells, a process involving the proteasome — a cellular complex that degrades unwanted or damaged proteins. This surge in protein turnover creates proteotoxic stress; the cell accumulates misfolded proteins that overwhelm its quality-control systems. This stress activates a pathway involving ATF4 and CHOP, two transcription factors normally turned on during endoplasmic reticulum stress (a cellular alarm triggered by protein overload). When researchers knocked out these genes using CRISPR, Nutlin-3-induced cell death was reduced, proving this stress pathway contributes to Nutlin's cytotoxicity. A genome-wide CRISPR screen also highlighted PSMD9, a component of the proteasome, as a key factor in Nutlin sensitivity — cells lacking PSMD9 were resistant to Nutlin-3, indicating that an active proteasome is necessary for the drug's full effect.

These findings led to rational combination strategies. Pairing Nutlin-3 with carfilzomib (a proteasome inhibitor) amplified cell death: by further weakening the proteasome, carfilzomib heightened the stress caused by Nutlin-3, boosting pro-apoptotic signals like CHOP and NOXA and causing dramatic apoptosis in sarcoma models (Ludwig et al., 2023).

Ferroptosis sensitivity: Nutlin-3 also sensitises tumours to ferroptosis, an iron-dependent form of cell death caused by lipid peroxidation. p53 activation by Nutlin-3 represses the cystine transporter SLC7A11, lowering the cell's antioxidant defences and making it more vulnerable to

ferroptosis inducers such as erastin. Pre-treating cells with Nutlin-3 followed by erastin led to markedly increased lipid ROS and cell death compared to either drug alone (He et al., 2022).

DNA-damage and extrinsic apoptosis pathways: Nutlin-3 also synergizes with chemotherapies such as doxorubicin. In breast cancer models, Nutlin-3 enhanced doxorubicin-induced apoptosis by boosting p53 activity (Lee et al., 2017). Interestingly, Nutlin-3 can also engage the related p73 tumor suppressor pathway: in some p53-mutant cancers, Nutlin-3 triggers apoptosis via p73 activation (Abrams et al., 2017). This suggests that MDM2 inhibitors may retain partial activity even when p53 is mutated, expanding their potential therapeutic reach.

These vulnerabilities are beneficial in therapy design: they reveal stress points that combination drugs (e.g., proteasome inhibitors or ferroptosis inducers) can exploit to achieve stronger tumor killing than Nutlin-3 alone.

Despite strong preclinical activity, Nutlin-3 was unsuitable for clinical use because of poor pharmacokinetic properties — it required very high doses for effect, had low oral bioavailability, and was cleared rapidly from the body (Urso et al., 2017). These issues prompted the development of next-generation MDM2 inhibitors (e.g., RG7112, idasanutlin, milademetan) with improved drug-like properties.

RG7112

RG7112 was the first clinical-stage, orally bioavailable MDM2 antagonist to enter human trials, derived directly from the Nutlin scaffold but optimised for improved binding and solubility. In preclinical studies, RG7112 bound MDM2 with nanomolar affinity, reactivated p53 signalling in MDM2-amplified models, and induced tumour growth inhibition (Ray-Coquard et al., 2012).

A landmark Phase I trial tested RG7112 as a neoadjuvant therapy in patients with MDM2-amplified well- or dedifferentiated liposarcoma (WDLPS/DDLPS). It clearly demonstrated increased intratumoral p53 and p21 expression and reduced tumor proliferation. Most patients experienced disease stabilization, meaning tumor growth was halted rather than reversed. This study provided pharmacodynamic proof that p53 can be reactivated in MDM2-amplified sarcomas.

However, clinical utility was hindered by frequent hematologic side effects (notably thrombocytopenia and neutropenia) that necessitated dose interruptions. High-dose requirements and variable oral absorption also limited long-term use, so more potent, better-tolerated compounds succeeded RG7112.

Idasanutlin

Idasanutlin (RG7388) is a more potent, pyrrolidine-core MDM2 inhibitor with high oral bioavailability. Unlike Nutlin-derived molecules, idasanutlin features a pyrrolidine core that improves its fit within the MDM2 binding pocket and enhances its drug-like properties (Ding et al., 2013). This structural innovation results in ~10-fold greater potency than RG7112 in cellular assays, with a reported MDM2 binding IC_{50} of ~6 nM. (IC_{50} is the concentration of drug needed to

inhibit 50% of its target activity — single-digit nanomolar values indicate extremely high potency, whereas earlier Nutlin compounds typically had IC_{50} values in the tens of nanomolar range.)

Idasanutlin also exhibits markedly better oral bioavailability, allowing for shorter and more convenient dosing regimens — most clinical protocols use five consecutive days of treatment in a 28-day cycle, rather than the prolonged schedules required for RG7112.

Notably, idasanutlin demonstrated favorable combinations with proteasome inhibitors and FGFR/CDK4 inhibitors (reflecting key resistance escape mechanisms in liposarcoma). Clinically, most data are from AML trials (~25% CR with cytarabine), but early-phase sarcoma data show stable disease and occasional regressions. Hematologic side effects persisted but were less frequent/severe with intermittent dosing (Phelps et al., 2015).

One example is pairing idasanutlin with carfilzomib, a drug that blocks the proteasome (the cell's protein-degrading system). This combination created high levels of proteotoxic stress and triggered much stronger apoptosis than either drug alone. Another promising approach is combining idasanutlin with inhibitors of the fibroblast growth factor receptor (FGFR) pathway. FGFR signaling is often upregulated in DDLPS, providing tumor cells an alternate survival route even when p53 is reactivated. In preclinical studies, combining idasanutlin with the FGFR inhibitor erdafitinib suppressed proliferation and induced apoptosis far more effectively than either drug alone, often achieving tumor regressions (Dadone-Montaudié et al., 2020). This synergy likely works as blocking FGFR removes one of the key pathways tumor cells use to resist p53-mediated stress.

Milademetan

Milademetan is a third-generation oral MDM2 inhibitor specifically optimized for increased potency and tolerability in MDM2-amplified sarcomas. Its primary innovation is an intermittent dosing strategy (3 days on, 11 days off: "3/14"), developed to allow periods of p53 activation for antitumor effect while reducing sustained toxicity, particularly to the bone marrow. This schedule was shown in clinical trials to dramatically lower the risk and severity of side effects such as low platelets and neutropenia compared to continuous exposures seen with earlier MDM2 inhibitors.

In a Phase I study focusing on patients with advanced solid tumors—including a large dedifferentiated liposarcoma (DDLPS) expansion cohort—milademetan demonstrated meaningful clinical activity:

- The overall disease control rate in DDLPS was as high as 58–62%, with a median progression-free survival nearing 7 months.
- A number of patients experienced durable stable disease, and modest tumor shrinkages were observed, even if objective response rates remained low—consistent with the primarily cytostatic nature of p53 monotherapy in these tumors.
- Side effect profiles were manageable, with the majority of adverse events being mild and the intermittent schedule notably decreasing the frequency of more serious treatment-related cytopenias.

The subsequent Phase III MANTRA trial, comparing milademetan against trabectedin in advanced DDLPS, confirmed that oral intermittent MDM2 inhibition was as effective as standard

chemotherapy in delaying tumor progression, but with fewer drug-related discontinuations and no treatment-related deaths. However, milademetan was not superior for progression-free survival or tumor response rates, so further development as a single agent for liposarcoma has been deprioritized (Somaiah et al., 2024).

Other MDM2 Inhibitors and Future Directions

Beyond Nutlin-3, RG7112, idasanutlin, and milademetan, several additional MDM2-targeted therapies and related strategies are under development. These compounds either refine the Nutlin-class mechanism or expand into dual inhibition of MDM2 and its homolog MDMX (also known as MDM4). Together, they represent the next wave of attempts to fully reactivate wild-type p53 in cancers where MDM2 overexpression drives tumorigenesis.

MI-77301 (SAR405838)

MI-77301 (SAR202) is a spirooxindole-based MDM2 inhibitor designed for increased potency and selectivity compared to earlier compounds. It achieves tumor regression by restoring the p53 transcriptional program, effectively inducing apoptosis in models of dedifferentiated liposarcoma (DDLPS) that retain wild-type TP53 and have MDM2 amplification. Its efficacy is dependent on the presence of intact p53, making patient selection critical. Despite promising preclinical results, clinical progression has been limited and development slowed to focus on more advanced analogs (Wang S et al., 2014).

BI-907828

BI-907828 is an optimized, long-acting oral derivative of MI-77301. It distinguishes itself by its ability to maintain sustained p53 activation over an extended period, leading to complete tumor regression in DDLPS patient-derived xenograft models. Early clinical studies report encouraging antitumor activity with durable responses and an acceptable safety profile. This compound represents an advanced candidate for combination therapies aimed at improving clinical outcomes in sarcomas harboring MDM2 amplification (Cornillie et al., 2020).

Navtemadlin (KRT-232 / AMG-232)

Navtemadlin (KRT-232) is an oral MDM2 inhibitor originally developed by Amgen (as AMG-232) and now advanced by Kartos Therapeutics. It is one of the most potent MDM2 antagonists reported to date, showing substantially higher activity in biochemical and cellular assays compared to RG7112 or idasanutlin. In preclinical studies, navtemadlin induced rapid p53 stabilization, cell-cycle arrest, and apoptosis across multiple MDM2-amplified tumor models. It is currently in a Phase III trial for myelofibrosis, where the therapeutic goal is to selectively eradicate malignant hematopoietic progenitor cells through p53 reactivation. Navtemadlin is also being studied in combination with radiation therapy for soft tissue sarcomas (NRG-DT001) to determine whether MDM2 inhibition can radiosensitise these tumors, paralleling the synergy seen with Nutlin-3 in preclinical systems (Verstovsek et al., 2022).

ALRN-6924 (Sulanemadlin)

Tumors often upregulate MDMX as an escape mechanism under selective pressure from Nutlin-class drugs. ALRN-6924 (sulanemadlin) is a stapled peptide that mimics the alpha-helical region of p53 that interacts with both MDM2 and MDMX, thereby displacing p53 from both inhibitors simultaneously. In a Phase I trial in wild-type p53 solid tumors, ALRN-6924 demonstrated favourable tolerability, with notably lower rates of thrombocytopenia than small-molecule MDM2 inhibitors. The trial reported a 59% disease control rate, including some complete and partial responses. Although ALRN-6924's development pivoted toward chemoprotection — exploiting its ability to transiently activate p53 in healthy tissues to shield them from chemotherapy toxicity — its dual-targeting concept remains highly relevant for overcoming resistance in MDM2-amplified cancers (Saleh MN et al., 2021).

Siremadlin (HDM201)

Siremadlin (HDM201) is a second-generation oral MDM2 inhibitor with high selectivity and potency, designed to minimise off-target effects. In MDM2-amplified sarcoma preclinical models, siremadlin activated p53 signalling, upregulated p21, and caused growth arrest or apoptosis. Its combination with DNA-damaging chemotherapy showed synergistic effects.

In Phase I/II studies, siremadlin produced early signs of activity in MDM2-amplified sarcomas using intermittent dosing schedules to manage cytopenias. It is being evaluated in both solid and hematologic malignancies (Stein et al., 2021).

APG-115

APG-115 is a selective oral MDM2 inhibitor that not only restores p53 activity but also exerts immunomodulatory effects, enhancing antitumor immunity. Preclinical studies demonstrate its ability to augment the efficacy of immune checkpoint inhibitors. Early clinical trials in patients with solid tumors, including sarcomas, have shown tolerable safety and preliminary evidence of durable disease control, especially when used in combination with immunotherapy (Cui et al., 2024).

AMG-232

AMG-232 is a high-affinity oral MDM2 inhibitor with one of the strongest reported p53-binding affinities in its class. In xenograft models, it achieved rapid p53 pathway activation and tumour shrinkage.

In a Phase I dose-escalation study, AMG-232 demonstrated on-target biomarker modulation and occasional partial responses in MDM2-amplified tumours. Combination studies, including with radiotherapy and targeted agents, are ongoing to enhance clinical benefit (Canon et al., 2015).

Resistance to MDM2 inhibitors

Drug resistance is a major clinical challenge for MDM2 inhibitor therapy in sarcoma. One predominant mechanism is the emergence of TP53 mutations during treatment: prolonged exposure to Nutlin-class inhibitors often leads to selection of new missense mutations within the

p53 DNA-binding domain, thereby inactivating its transcriptional and apoptotic functions and rendering MDM2 inhibition ineffective (Vassilev et al., 2004). Laboratory studies have repeatedly demonstrated the evolution of such p53 mutations following Nutlin-3 adaptation, highlighting the need either to deliver combination or time-limited therapies that prevent this evolutionary escape, or to target mutant p53 directly with agents like APR-246 (Ludwig et al., 2023).

A second escape route is MDMX (MDM4) upregulation: as Nutlin-class drugs only break the p53-MDM2 interaction, many tumors rapidly increase MDMX expression to continue suppressing p53 even when MDM2 is blocked (Saleh MN et al., 2021). Dual MDM2/MDMX antagonists, such as ALRN-6924, are now in trials specifically to circumvent this bypass.

Resistance can also arise from shifts in apoptotic threshold. As p53-driven apoptosis increases, tumor cells respond by upregulating anti-apoptotic proteins such as BCL-2 and BCL-XL. Combining MDM2 inhibitors with BH3 mimetics (such as venetoclax or navitoclax) can block these survival pathways and restore apoptotic death (Bill et al., 2016).

Oncogenic signaling crosstalk also facilitates therapeutic escape. In liposarcomas bearing CDK4 amplification or elevated FGFR activity, additional pathway activation makes tumor cells less reliant on the MDM2–p53 axis. Rational combinations with CDK4/6 inhibitors (e.g., palbociclib), or FGFR inhibitors (e.g., erdafitinib), have shown resensitization in preclinical models.

Finally, dosing schedule is key: continuous MDM2 inhibitor exposure accelerates the selection of resistant clones, while intermittent dosing, such as the 3/14 milademetan protocol, preserves efficacy and delays resistance.

Evolving Strategies

Emerging strategies for resistance include dual MDM2/MDMX inhibition by new-generation molecules, which blocks both arms of p53 repression and may preempt the most frequent bypass. Temporal sequencing and dynamic (primed or pulse) combination regimens are now utilised to heighten tumor vulnerability, for example, by first using an MDM2 inhibitor to synchronise sarcoma cells, then applying a targeted or cytotoxic second agent.

Beyond apoptosis, leveraging sensitisation to *extrinsic* death via p53-driven upregulation of death receptors like TRAIL-R2, in combination with TRAIL agonists or immune modulators, is an active area of preclinical research (Ray-Coquard et al., 2012). Similarly, combining MDM2 inhibition with immunotherapy (e.g., PD-1/PD-L1 blockade) takes advantage of p53's role in fostering a pro-immunogenic tumor environment, and such approaches have entered clinical trials.

Finally, alternative cell death pathways, such as ferroptosis, are being targeted. Nutlin-class compounds sensitise cells to ferroptosis inducers (e.g., erastin), providing another tactic against apoptosis-resistant or heavily pretreated tumors (Ludwig et al., 2023). Adaptive, patient-specific therapy regimens—shaped by real-time molecular monitoring—are under development to further individualise and prolong MDM2 pathway responses. These are summarised in Table 2.

Table 2. Mechanisms of resistance to MDM2 inhibition and strategies to overcome them

Cause of resistance	Mechanism	Impact on Therapy	Potential Strategies
New TP53 mutation	Mutations in p53's DNA-binding domain during treatment	Prevents p53 activation; drug becomes ineffective	Shorten exposure; target mutant p53 (e.g., APR-246)
Upregulated MDMX expression	Overexpression of MDMX replaces MDM2's role	Still blocks p53 despite MDM2 drug	Use dual MDM2/MDMX inhibitors (e.g., ALRN-6924)
Higher anti-apoptotic proteins	Increased BCL-2/BCL-XL proteins block p53's apoptotic signal	Limits cell death despite p53 activation	Combine with pro-apoptotic drugs (e.g., venetoclax, navitoclax)
Alternate survival pathways	FGFR, CDK4, PI3K pathways activated	Cancer growth bypasses p53 dependency	Add pathway-specific inhibitors
Continuous dosing	Constant exposure favours resistant clones	Resistance appears faster	Use intermittent dosing schedules (e.g., milademetan 3/14 schedule)

Conclusion

The evolution from Nutlin-3 to second-generation idasanutlin and third-generation milademetan has firmly established the principle of pharmacologic p53 reactivation in cancer therapy. In MDM2-amplified sarcomas such as liposarcoma — where TP53 remains wild-type — these

drugs exploit a unique vulnerability: the tumor's dependence on MDM2 overexpression to suppress p53. By blocking the p53–MDM2 interaction, they restore p53's tumor-suppressive functions, triggering cell-cycle arrest, senescence, or apoptosis through downstream targets such as p21 and PUMA.

Preclinical models have even demonstrated complete tumor regression with potent p53 reactivation, while clinical trials have shown prolonged disease stabilization in a subset of patients. However, consistent tumor shrinkage with monotherapy remains uncommon. Therapeutic challenges include the intrinsic p53–MDM2 (and MDMX) feedback loop, alternative tumor survival pathways, and on-target toxicities — particularly dose-limiting thrombocytopenia from p53 activation in normal tissues. Intermittent dosing, as with milademetan, has shown that efficacy and tolerability can be balanced, as confirmed by its Phase III trial, which demonstrated comparable activity but better safety than standard chemotherapy.

Future progress will rely on combination strategies that amplify p53-driven stress, such as pairing MDM2 inhibitors with proteasome inhibitors, ferroptosis inducers, TRAIL-receptor agonists, BH3 mimetics, or targeted kinase inhibitors. Dual MDM2/MDMX inhibitors may overcome resistance mediated by MDMX upregulation, and biomarker-guided patient selection — focusing on high MDM2 amplification, low MDMX expression, and intact p53 — will be essential for maximizing benefit .

Next-generation agents like BI-907828 and navtemadlin promise greater potency, improved pharmacokinetics (Alaseem AM, 2023), and potential synergy with immune checkpoint blockade, enabling p53 reactivation to work in concert with immune-mediated tumor clearance. With these refinements, the field is moving toward liberating the guardian of the genome into durable clinical benefit for sarcoma patients.

References

1. Wu L, Maki CG. MDM2 oncoprotein functions. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000–2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6130/

2. Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. p53 signaling in cancer progression and therapy. Cancer Cell International. 2021 Dec 24;21:703. Available from: https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02396-8

3. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study. Lancet Oncol. 2012 Nov;13(11):1133-1140.

4. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017 Jul 3;10(1):133. Available from:

https://pubmed.ncbi.nlm.nih.gov/28673313/

5. Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016 Jun;6(6):a026336. doi:10.1101/cshperspect.a026336

6. Yao Y, Zhang Q, Li Z, et al. MDM2: current research status and prospects of tumor treatment. Cancer Cell Int. 2024 May 13;24:170. Available from: https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03356-8

7. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: News and perspectives. Pathologica. 2020 Nov 3;113(2):70-84.

8. Gambella A, Bertero L, Rondón-Lagos M, Verdun Di Cantogno L, Rangel N, Pitino C, et al. FISH diagnostic assessment of MDM2 amplification in liposarcoma: Potential pitfalls and troubleshooting recommendations. Int J Mol Sci. 2023 Jan 10;24(2):1342.

9. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-848.

10. Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: Perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019 Apr 16;12:2903-2910.

11. Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res. 2021 Oct 1;27(19):5236-5247.

12. Hanna GJ, DeCaprio JA, Mei JHM, McGreivy JS. An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma who have failed treatment with anti-PD-1/L1 immunotherapy. J Clin Oncol. 2019 May 26;37(15_suppl):TPS9602.

13. Bill KLJ, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, et al. SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res. 2016 Mar 1;22(5):1150-1160.

14. Boehringer Ingelheim. This study aims to find the best dose of BI 907828 (Brigimadlin) in patients with different types of advanced cancer (solid tumors). ClinicalTrials.gov; 2025 Aug 6. Report No.: NCT03449381. Available from: https://clinicaltrials.gov/study/NCT03449381

15. Novartis Pharmaceuticals. Study to determine and evaluate a safe and tolerated dose of HDM201 in patients with selected advanced tumors that are TP53wt. Bethesda (MD): U.S. National Library of Medicine; 2021 May 21. Available from:

https://clinicaltrials.gov/study/NCT02143635

16. Fang DD, Tang Q, Kong Y, Wang Q, Gu J, Fang X, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019 Nov 28;7(1):327.

17. Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs. 2019 Jul;38(3):831-843.

18. Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, Rubbi CP, et al. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitizes laryngeal carcinoma cells harboring wild-type p53. Br J Cancer. 2010 Jul 13;103(2):186-195.

19. Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, et al. Anticancer effects of the p53 activator Nutlin-3 in Ewing's sarcoma cells. Eur J Cancer. 2011 Jun;47(9):1432-1441.

20. Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Moreno Tellez C, et al. Proteasome inhibition sensitizes liposarcoma to MDM2 inhibition with Nutlin-3 by activating the ATF4/CHOP stress response pathway. Cancer Res. 2023 Aug 1;83(15):2543-2556.

21. He W, Shu W, Xue L, Wang Y, Chai Y, Wu H, et al. Synergistic effect of erastin combined with Nutlin-3 on vestibular schwannoma cells as p53 modulates erastin-induced ferroptosis response. J Oncol. 2022 Mar 21;2022:7507857.

22. Lee DM, Kim IY, Seo MJ, Kwon MR, Choi KS. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. Exp Mol Med. 2017 Aug 11;49(8):e365.

23. Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, et al. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget. 2017;8(45):76525-76557.

24. Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, et al. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. Oncotarget. 2017 May 11;8(27):44232-44241.

25. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013 Jul 25;56(14):5979-5983.

26. Phelps DA, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, et al. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models

of childhood sarcoma. Pediatr Blood Cancer. 2015 Apr;62(8):1345-1352.

27. Dadone-Montaudié B, Laroche-Clary A, Mongis A, Chamorey E, Di Mauro I, Chaire V, et al. Novel therapeutic insights in dedifferentiated liposarcoma: A role for FGFR and MDM2 dual targeting. Cancers (Basel). 2020 Oct 20;12(10):3058.

28. Somaiah N, et al. MDM2–p53 in liposarcoma: The need for targeted therapies. Cancer Treat Rev. 2024.

29. Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, et al. SAR405838: an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-5865.

30. Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, et al. Anti-tumor activity of the MDM2–TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clin Transl Oncol. 2020 Apr;22(4):546-554.

31. Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, et al. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901.

32. Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin CC, et al. Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia. Clin Cancer Res. 2021 Dec 2;28(5):870-881.

33. Cui Y, Shao X, Yang H, Xin J, Liu Y, Zhang M, et al. MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia. Front Pharmacol. 2024 Jul 31;15:1441383.

34. Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, et al. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther. 2015;14(3):649-658.

35. Alaseem AM. Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens. Saudi Pharm J. 2023 Oct;31(10):101790.